Blueheel1
1 day ago
yes, i miss his posts also. he is a technical guy - and while that stuff is beyond my pay grade, he did a great job of laying out what the charts were saying. For what it's worth, i'm not sure we want to know his view of what the current chart is suggesting :) But, seems like a great guy and with a lot of expertise in that area.
I also miss SALTZ, maybe was the best across any of the message boards. He nailed it - said that Nader was killing the company, and sold out (I think) in the $3 range. There are a few others that have been very good over time but who no longer post - many I can only assume have given up on CytoDyn, which i can't say i blame them at this point. Maybe they're just in constant psycho-therapy as a result of this investment and no longer have the time to post.....
justdafactss
3 days ago
What about Brucie pumping Operation Warp Speed?---
Small Biotech Stock CytoDyn Soars on ‘Warp Speed’ Comment
By Michael Wursthorn
Updated Aug. 26, 2020 9:18 pm ET
The market for small biotechs working on coronavirus treatments is so hot that sometimes all it takes is a whisper to send a stock soaring.
So it was with CytoDyn Inc. , which climbed more than 20% after a former adviser told television host Dr. Drew Pinksy on Thursday that he thought the company would move forward with a federal-government program aimed at fast- tracking virus treatments.
CytoDyn isn't being considered for the program, known as Operation Warp Speed, according to a senior administration official.
Yet in the quick-punch world of retail investing, the video clip of the former adviser, Bruce Patterson , has already gone viral. Investors who closely follow the company shared it on social media and message boards, including Investors Hub, a forum popular with penny-stock traders. Shares of CytoDyn rallied 13% to $3.43 a share on Friday, notching the company's biggest daily gain in about a month, before rising another 12% on Monday.
CytoDyn Shares have plateaued since then, declining a more than 2% over the last two trading sessions.
Operation Warp Speed is a federal initiative to accelerate the development and manufacturing of drugs and vaccines for Covid-19, which has claimed more than 175,000 lives in the U.S. Through the program, the government has given funding to companies such as Moderna Inc. , Novavax Inc. and Regeneron Pharmaceuticals Inc.
The senior administration official said CytoDyn had only completed a preliminary qualification for being included in the initiative. The Vancouver, Wash ., company had submitted information through a so-called CoronaWatch, a program run by the Biomedical Advanced Research and Development Authority , or Barda, to assess the viability of drugs and therapeutics that might be effective against Covid-19, the official said. Technical experts reviewed the submission and opted not to proceed further at this time, the official added.
The team responsible for reviewing the materials makes clear to companies that submissions are for informational purposes only and don't lead to funding on their own, the official added. Companies must apply to specific grant programs to receive funding, the official said, which CytoDyn hasn't done at this time.
Dr. Patterson told The Wall Street Journal that he helped arrange an initial exchange of information between CytoDyn and Barda. He hadn't been involved in further discussions, he said.
CytoDyn declined to comment on the exchange or on any communication with Operation Warp Speed.
" CytoDyn received an email. I received an email from Operation Warp Speed. So yes they are aware of it," Dr. Patterson said in the video. "And I think we'll move forward with them."
The company hired Dr. Patterson as an adviser, in addition to hiring his company, IncellDx, to provide diagnostic services. CytoDyn and Dr. Patterson said his tenure as a consultant ended in May. CytoDyn also no longer uses Dr. Patterson's company for diagnostic services.
An April securities filing disclosed that Dr. Patterson was a CytoDyn shareholder.
In the interview with the Journal, Dr. Patterson said he never received paperwork regarding his ownership in CytoDyn . "I've gotten little to no paperwork regarding that," he said. "I don't think of it as real."
On the question of Dr. Patterson's share ownership, Arian Colachis , CytoDyn's general counsel, pointed to the April filing.
"The document speaks for itself, and we have no further comment," she said.
Write to Michael Wursthorn at Michael.Wursthorn@wsj.com
(END) Dow Jones Newswires
08-26-20 1145ET
Copyright (c) 2020 Dow Jones & Company, Inc.
Blueheel1
5 days ago
i think you're right. I have always believed there is value in the drug itself. In the right hands, it could create a lot of value for investors. I placed way too much focus on the drug, and not nearly enough on the leadership side when making my investment decisions. But, what I have learned (the hard way) is that for any company to succeed, you must have both - a great product, and great execution by a solid leader.
What i cannot figure out now is whether the company (and my investment by extension) can survive NPs disastrous moves. I'm not discounting the FDA and their hatred of CYDY - but I am convinced that if we had a very credible leader in place, the regulators would have treated us completely differently. They have seen us as a problem child for many years - mostly because of the way NP has behaved.
I remain very concerned, but i don't think anyone knows for sure how this will play out - despite some saying they do.
$5.95akadawson-m
5 days ago
To reiterate
I've been reading posts on other boards and I have to say that there were so many smart people who had invested in CYDY three or + years ago. They definitely were ahead of the curve or more skeptical of NP and his wiley ways. Some of us, like me, only focused on the efficacy of Leronlimab - believing its Lazarus qualities while others had the right focus looking at NP and saying "What is he doing?" My inner voice still says Leronlimab is the real thing but how is it going to play out, now?
Today's court documents have harpooned both Nader and FDA members in separate ways to CYDY's downfall. The longs take it on the chin because these FDA blowhards, who incidentally are the ones in-charge and making new rules (not observing the rules) have played whack-a-mole with CYDY and thus, maybe killing the efficacy of Leronlimab, forever.
Monroe1
5 days ago
Yes, I expect some interviews with Nader et al....ET AL. Going to be quite the interesting story should one ever get published.
Some who don't expect it may get an interview as well. Be ready!! FDA and bashers will follow the Nader interview most likely.
May well trigger some other investigations to dig some more and make a few adjustments. Probably going to be a lot of squirming trying to get the stories straight.
Meanwhile, Sidley takes good notes and may well have some contributions to add to the story.
So in the interim, keep up the incrimination bashers ,and oh yes, thanks for the cheapies anytime.
In the interim, Dr. Jay is slaving away. Get ready.
$CYDY$ 2024